Multivariable analysis according to the Fine and Gray model of variables affecting GVHD occurrence
| . | Grade 2-4 aGVHD . | Grade 3-4 aGVHD . | Mod-sev cGVHD . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | Multivariable . | Multivariable . | Multivariable . | ||||||
| Variable . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Donor age, per 5-y increase | 1.16 | 1.03, 1.31 | .015 | 1.09 | 0.95, 1.25 | .238 | 1.10 | 0.98, 1.24 | .112 |
| Recipient age, per 5-y increase | 0.99 | 0.91, 1.07 | .723 | 1.13 | 0.90, 1.42 | .285 | 1.00 | 0.91, 1.11 | .947 |
| Recipient sex: female vs male | 1.09 | 0.97, 1.23 | .152 | 1.02 | 0.76, 1.35 | .914 | 1.13 | 0.64, 2.01 | .670 |
| Disease type: myeloid vs lymphoid | 0.75 | 0.60, 0.96 | .020 | 0.93 | 0.43, 2.00 | .853 | 1.05 | 0.71, 1.56 | .792 |
| PR vs CR status before HAPLO | 0.96 | 0.68, 1.36 | .830 | 2.02 | 0.90, 4.52 | .088 | 1.00 | 0.53, 1.89 | .996 |
| PD vs CR status before haplo-SCT | 0.88 | 0.69, 1.13 | .324 | 0.99 | 0.73, 1.35 | .946 | 0.97 | 0.65, 1.45 | .879 |
| Sex D/R: F→M vs not F→M | 1.13 | 0.79, 1.60 | .512 | 1.35 | 0.57, 3.15 | .494 | 2.58 | 1.91, 3.48 | <.001 |
| CMV recipient positive vs negative | 0.89 | 0.79, 1.01 | .072 | 1.42 | 0.65, 3.10 | .383 | 1.89 | 1.40, 2.55 | <.001 |
| HCT-CI ≥3 vs <3 | 1.38 | 0.96, 1.98 | .084 | 1.55 | 1.09, 2.20 | .015 | 1.53 | 0.89, 2.61 | .121 |
| Source: PBSC vs BM | 1.74 | 1.21, 2.50 | .003 | 1.86 | 1.36, 2.55 | <.001 | 1.09 | 0.64, 1.86 | .745 |
| Conditioning: MAC vs RIC/NMA | 1.52 | 0.95, 2.43 | .079 | 2.53 | 1.46, 4.41 | .001 | 1.81 | 1.07, 3.05 | .027 |
| . | Grade 2-4 aGVHD . | Grade 3-4 aGVHD . | Mod-sev cGVHD . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | Multivariable . | Multivariable . | Multivariable . | ||||||
| Variable . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| Donor age, per 5-y increase | 1.16 | 1.03, 1.31 | .015 | 1.09 | 0.95, 1.25 | .238 | 1.10 | 0.98, 1.24 | .112 |
| Recipient age, per 5-y increase | 0.99 | 0.91, 1.07 | .723 | 1.13 | 0.90, 1.42 | .285 | 1.00 | 0.91, 1.11 | .947 |
| Recipient sex: female vs male | 1.09 | 0.97, 1.23 | .152 | 1.02 | 0.76, 1.35 | .914 | 1.13 | 0.64, 2.01 | .670 |
| Disease type: myeloid vs lymphoid | 0.75 | 0.60, 0.96 | .020 | 0.93 | 0.43, 2.00 | .853 | 1.05 | 0.71, 1.56 | .792 |
| PR vs CR status before HAPLO | 0.96 | 0.68, 1.36 | .830 | 2.02 | 0.90, 4.52 | .088 | 1.00 | 0.53, 1.89 | .996 |
| PD vs CR status before haplo-SCT | 0.88 | 0.69, 1.13 | .324 | 0.99 | 0.73, 1.35 | .946 | 0.97 | 0.65, 1.45 | .879 |
| Sex D/R: F→M vs not F→M | 1.13 | 0.79, 1.60 | .512 | 1.35 | 0.57, 3.15 | .494 | 2.58 | 1.91, 3.48 | <.001 |
| CMV recipient positive vs negative | 0.89 | 0.79, 1.01 | .072 | 1.42 | 0.65, 3.10 | .383 | 1.89 | 1.40, 2.55 | <.001 |
| HCT-CI ≥3 vs <3 | 1.38 | 0.96, 1.98 | .084 | 1.55 | 1.09, 2.20 | .015 | 1.53 | 0.89, 2.61 | .121 |
| Source: PBSC vs BM | 1.74 | 1.21, 2.50 | .003 | 1.86 | 1.36, 2.55 | <.001 | 1.09 | 0.64, 1.86 | .745 |
| Conditioning: MAC vs RIC/NMA | 1.52 | 0.95, 2.43 | .079 | 2.53 | 1.46, 4.41 | .001 | 1.81 | 1.07, 3.05 | .027 |
HR associated with P < .05 are denoted by boldface.
D/R, donor/recipient; Mod-sev, moderate-severe.